Formulation and evaluation of chewable tablets of Desloratadine prepared by aqueous and non-aqueous techniques
In the modern era, chewable tablets are preferred over conventional dosage forms by pediatric, geriatric and bedridden patients due to difficulty in swallowing, lesser amount of water for swallowing medications as well as unable to tolerate the bitter taste of certain drugs. Chewable tablets of Desloratadine (DS) were formulated by aqueous and non-aqueous granulation method using water paste and Isopropyl alcohol (IPA) as a wetting agents respectively. Desloratadine is used to treat the symptoms of allergy such as sneezing, watery eyes. In the recent research, we have formulated eight trials by various concentrations of excipients. For instance; lactose, talcum, magnesium stearate, blue color, flavor, aspartame, mannitol, avicel 101 and polyvenylpyrollidine (PVP). Pre-compression and post compression parameters (thickness, hardness, friability weight variation and drug content) of the formulations were evaluated. B3 was our optimum dosage form because its Hausner’s ratio, compressibility index, bulk density, tap density, angle of repose have optimum values i.e. 1.01, 5.1%, 0.66(g/cc), 0.69(g/cc), 26.1º respectively and post-compression i.e. thickness, hardness, friability weight variation and drug content have values, 2.9mm, 3.9(kg/cm²), 0.6%, 99.5% respectively. Tablets prepared by wet granulation technique showed reasonable release profile i.e. 100% within the required time i.e. 2 hours. Moreover, organoleptic evaluation of all formulations were performed.
Keywords: Desloratadine, chewable, magnesium stearate, aspartame, compressibility, granulation.
2. Dykewicz MS et al:Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology, 1998; 81(5):478-518.
3. Van CP et al: Consensus statement on the treatment of allergic rhinitis. Allergy, 2000; 55(2):116-134.
4. Gonzalez M and Estes K. Pharmacokinetic overview of oral second-generation H1 antihistamines. International journal of clinical pharmacology and therapeutics, 1998; 36(5):292-300.
5. Geha RS and MeltzerEO. Desloratadine: a new, nonsedating, oral antihistamine. Journal of Allergy and Clinical Immunology, 2001; 107(4):751-762.
6. Cvetkovic M et al: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug metabolism and disposition, 1999; 27(8):866-871.
7. Kreutner W et al: Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist2nd Communication: Lack of central nervous system and cardiovascular effects. Arzneimittelforschung, 2000; 50(05):441-448.
8. Affrime M et al: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clinical pharmacokinetics, 2002; 41(1):13-19.
9. Lakshmanan S and PandeyM. Analysis of startup oscillations in natural circulation boiling systems. Nuclear Engineering and Design, 2009; 239(11):2391-2398.
10. Nazir T. Extended Release Orally Disintegrating Dosage Forms are Potential Techniques to Deliver and Maintain the Therapeutic Ranges of Plasma Drug Concentrations. J App Pharm, 2015; 7:001.
11. Kandi M et al: Formulation and Evaluation of Chewable Tablet of Metformin HCl Using Stevia by Different Techniques. International Journal of PharmTech Research, 2013; 5(3):1364-1372.
12. Radke R, JadhavJ and ChajeedM. Formulation and evaluation of orodispersible tablets of baclofen. Int J Chem Tech Res, 2009; 1(3):517-21.
13. Chandrasekaran A et al: Post market in vitro equivalency evaluation of paracetamol tablets in kedah, Malaysia. Int J Pharm Sci Nanotech, 2011; 4(2):1403-1407.
14. Etman MA et al: Formulation of Desloratadine Oral Disintegrating Tablets. Journal of Applied Pharmaceutical Science, 2014; 4(11):054-061.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).